Ferran Astorga Jeannette has submitted a filing detailing a recent transaction involving phantom stock units, which is significant for both the individual and the broader context of executive compensation within the pharmaceutical industry.
Ferran Astorga Jeannette is associated with Zoetis Inc., a company that operates in the pharmaceutical preparations sector. The recent filing, dated October 13, 2026, under the accession number 0001628280-26-065805, highlights the ongoing financial activities of Astorga as an Executive Vice President of Zoetis.
What the Filing Says
The filing indicates that on October 9, 2026, Astorga acquired approximately 52.98 phantom stock units at a price of $26.17 per unit. Following this transaction, Astorga now holds a total of 2,349.14 shares of common stock. The filing notes, "These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service." This structure allows for flexibility in investment while linking compensation to the performance of Zoetis' stock.
Impact
This transaction may influence various stakeholders, including Zoetis' board members, investors, and employees. The ongoing commitment of Astorga to the company's performance through phantom stock units may enhance confidence among investors and employees alike. Additionally, it reflects broader trends in executive compensation strategies within the pharmaceutical preparations industry.
What's Next
The filing does not say what happens next.